DOCSLIB.ORG

Annual Meeting and Toxexpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Meeting and Toxexpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research Directory Baltimore, Maryland March 12–16, 2017 56th Annual Meeting and ToxExpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research • Molecular Imaging • Radiochemistry • Luminescence • in vivo, in vitro • Fluorescence • X-Ray, MicroCT • Biomarker Assessment • LC-MS/MS, Multiplex • GLP Toxicology • Acute, subchronic, chronic • PK/PD • ELISA • Histology • Flow Cytometry • Cryo- and Paraffin sections • Safety Pharmacology • Histopathology • Immunohistochemistry • Bioanalytical Chemistry Offices in USA Europe Australia +1 717-798-9990 +49 89 122 287 690 +61 3 9988 1800 [email protected] Booth 2046 AAALAC accredited GLP- compliant Directory SOT Mobile Event App! ToxExpo Hours Access information from the SOT Program, The Monday, March 13 9:15 AM to 4:30 PM Toxicologist, and ToxExpo Directory via your mobile device. Tuesday, March 14 9:15 AM to 4:30 PM Wednesday, March 15 9:15 AM to 4:30 PM Table of Contents Supporters .............................................................................. 2 Exhibit Hall Map ................................................................... 4 2017 Exhibitors ...................................................................... 6 General Information ..........................................................10 Exhibitor-Hosted Sessions ..............................................14 Exhibitor Descriptions .....................................................24 Exhibitor Product/Service Category Listing ........ 128 ToxExpo.com Available for download from Connecting toxicologists the Apple and Google Play app stores. with solution-based suppliers around the globe 24/7/365 Access via Mobile Web www.toxicology.org/mobileapp Follow @ToxExpo and @SOToxicology Tweet with #2017SOT and #toxexpo The purpose of the Society of Toxicology's exhibit program (ToxExpo) is to further the education of scientists working scientific fields relevant to toxicology and to support the mission of the Society. Exhibits are required to be educational in character and relevant to the science of toxicology. This directory, its contents, and graphics are ©2017 by the Society of Toxicology as proprietary products of SOT. All rights are reserved. The content of this directory may not, in whole or in part, be reproduced, copied, disseminated, entered into a computer database, or otherwise utilized, in any form or manner or by any means except for the user’s individual, personal, and confidential reference. No text or graphics may be copied or used without written permission from the Society of Toxicology. For further information, please contact SOT Headquarters. The Society of Toxicology appreciates the generous contributions of the 56th Annual Meeting Supporters: (Supporter listing as of February 20, 2017) Platinum ($5,000–9,999) The Allergan Foundation Merck Amgen MilliporeSigma Burroughs Wellcome Fund Takeda Eli Lilly and Company ToxServices LLC Genentech, Inc. US Food and Drug Administration Gold ($2,500–4,999) AbbVie ExxonMobil Biomedical Sciences, Inc. CiToxLab Gilead Products and services 365 days of the year—Visit ToxExpo.com DuPont Haskell Global Centers for Health & Gradient Environmental Sciences 2 MPI Research Eastman Charitable Foundation MRIGlobal EUROTOX 2017 NSF International Exponent, Inc Silver ($2,000–2,499) Academy of Toxicological Sciences (ATS) Human Toxicology Project Consortium (HTPC) American College of Toxicology (ACT) Safety Pharmacology Society (SPS) Battelle SRC, Inc Calvert Labs, Inc. Society of Toxicologic Pathology (STP) DILIsym Services, Inc. Teratology Society (TS) Environmental Mutagenesis and Genomics Society (EMGS) Contributor ($1,000–1,999) Eisai Research Institute for Fragance Materials, Inc. ♦ 2017 Annual Meeting and ToxExpo Diamond Supporters ($10,000 or more) t Diamond-Level Supporter Exhibitors Boehringer Ingelheim Pharmaceuticals, Inc. t Bristol-Myers Squibb t Charles River Colgate-Palmolive Company 3 t Drug Safety Research and #toxexpo Development, Pfizer Inc. t National Institute of Environmental #2017SOT Health Sciences t SOT Endowment Fund Sanofi Syngenta Floor Plan Exhibit Hall • Level 100 ToxExpo Hours: Monday to Wednesday 9:15 AM to 4:30 PM ToxExpo 2017 Poster Exhibitor Service Sales/Show Pick Up Desk Center Management O ce Networking Time: Tuesday 12:30 PM to 1:20 PM You are encouraged to connect and engage with your colleagues today between sessions as only networking events and Exhibit Hall activities are scheduled during this time. SOT Pavilion RC/SIG/SS Power Bar Near Aisle 1200 2489 Poster 2391 2490 Boards The Power Bar is a destination and meeting place in the Exhibit Hall with lounge furniture and tables equipped 2389 2488 with power to charge for your phone and devices while you network. POSTER POSTER Food Services | Monday to Wednesday Poster Retrieval Table BOARDS BOARDS Concession Stands 9:15 AM to 2:30 PM P501–P570 P601–P670 PURPLE GOLD Complimentary Coffee Beginning at 9:15 AM Complimentary Lemonade and Popcorn Beginning at 2:30 PM 2271 2370 2571 2670 2671 2169 2269 2368 2469 2568 2569 2668 2669 2266 2167 2267 2366 Global Gallery of Toxicology 2467 2566 2667 2165 2264 2265 2364 2465 2564 2565 2664 2665 Products and services 365 days of the year—Visit ToxExpo.com 2063 2563 2662 2663 2160 4 2161 2260 CiToxLAB Mobile 2461 2560 2661 2057 2158 2159 2258 2257 Charging 2558 2559 2658 2457 2156 Station 2556 2557 2656 Espresso Thank You Cart 1953 2053 2152 2153 2552 2652 2050 2250 MPI 2451 2551 CiToxLAB—Lanyards PreLabs—Attendee Bags ToxServices LLC—Notepads 1951 2051 2150 2151 Research 2550 2650 2651 1949 2149 2248 2449 2548 2649 2046 2243 1947 2147 2246 2447 2546 2547 2646 2647 2045 2144 Sinclair 2145 2244 2545 2644 1843 2443 2542 1943 2043 2142 2543 2642 ToxExpo 2040 2641 2041 2140 2141 2240 1939 Scientific Poster Boards: 1839 2038 2139 2238 2239 2439 2538 2539 2638 Entrance 2336 Detailed Poster Board information can WuXi 1837 1934 2037 2437 2536 2637 POSTER BOARDS 1849 AISLE 1900 AISLE 2000 2134AISLE 2100 2135 2234AISLE 2200 2235 AISLE 2300 AISLE 2400 AISLE 2500 2535 2634 AISLE 2600 Mobile Charging Station be found in the Program on pages 81–86. Poster Retrieval Table AppTec 1835 1935 2035 2435 2534 2635 P401–P456 | ORANGE 2032 2332 1833 1932 1933 2033 2132 2233 2433 2532 2633 1728 2228 2229 2528 2529 2628 1627 1727 1826 Charles River 2027 2126 2127 2427 327 426 427 526 527 626 827 926 1726 1825 2226 2324 2527 2626 2627 2225 2524 325 424 425 524 525 624 825 924 1625 1724 1725 2125 2224 2425 2525 2624 2625 1822 423 522 623 722 723 822 POSTER BOARDS 1622 1723 SNBL USA 2322 2623 1521 2121 2220 2221 221 320 US EPA 421 520 521 620 621 720 721 920 Power Bar 1620 Southern 1721 1820 Instem ITR 2019 2320 Envigo 2620 319 818 819 P301–P370 | GRAY 1619 1819 1919 2519 219 318 519 618 719 918 1719 1818 2618 Canada 2415 417 516 716 1616 2216 Covance 2617 615 1515 314 315 414 415 514 515 614 715 814 914 915 Promega 1115 1214 1315 1414 1614 Battelle 1814 Toxikon 1915 Smithers 2113 2214 2213 2614 2615 AISLE 200 AISLE 300 AISLE 500 AISLE 400 AISLE 600 AISLE 700 AISLE 800 213 712 813 1012 1013 AISLE 1500 AISLE 1600 1613AISLE 1700 1713 AISLE 1800 1813 AISLE 1900 2012AISLE 2000 2013 AISLE 2100 AISLE 2200 AISLE 2300 AISLE 2400 AISLE 2500 2513 AISLE 2600 312 313 412 413 512 513 612 613 713 812 912 913 1113 1212 1313 1412 1513 1612 1812 1913 2212 2612 2613 ToxExpo 2411 2510 2611 ♦ 2508 2608 AISLE 900 2407 2507 AISLE 1000 AISLE 1200 207 306 307 406 407 506 507 606 607 706 707 806 807 906 907 1006 1007 AISLE 1100 1107 1206 MilliporeSigm 1907 2006 2506 2606 2607 Entrance POSTER BOARDS POSTER BOARDS 205 304 305 404 405 504 505 604 605 704 805 904 905 1004 1005 1102 1105 1204 1803 2004 2605 1903 1003 1103 1202 P201–P256 | GREEN P101–P170 | BLUE BioReliance/EMD 2002 2603 Co ee Cart ToxExpo Entrance ♦ Diamond-Level Supporter Prize Drawing Win $500! ♦ Drawings to take place on Monday, Tuesday, and Wednesday in the ToxExpo. Win $500 American Express Gift Card awarded each day. $500! Drop your business cards in the ToxExpo prize drawing boxes found in all Diamond-Level Exhibitor Supporter booths, see ♦ on map. ToxExpo 2017 Poster Exhibitor Service Sales/Show Pick Up Desk Center Management O ce Booth 806 Booth 1825 SOT Pavilion RC/SIG/SS Poster 2391 2490 2489 Booth 2447 Booth 2489 Boards 2389 2488 ♦ Booth 2258 POSTER POSTER Poster Retrieval Table BOARDS BOARDS P501–P570 P601–P670 PURPLE GOLD 2271 2370 2571 2670 2671 2169 2269 2368 2469 2568 2569 2668 2669 2266 2167 2267 2366 Global Gallery of Toxicology 2467 2566 2667 2165 2264 2265 2364 2465 2564 2565 2664 2665 2063 2563 2662 2663 2160 2161 2260 CiToxLAB Mobile 2461 2560 2661 5 2057 2158 2159 2258 ♦ 2257 Charging 2558 2559 2658 2457 2156 Station 2556 2557 2656 Espresso Cart 1953 2053 2152 2153 2552 2652 2050 2250 MPI 2451 2551 1951 2051 2150 2151 Research 2550 2650 2651 #toxexpo 1949 2149 2248 2449 2548 2649 2046 2243 1947 2147 2246 ♦ 2447 2546 2547 2646 2647 2045 2144 Sinclair 2145 2244 2545 2644 1843 2443 2542 1943 2043 2142 2543 2642 2040 2641 2041 2140 2141 2240 1939 #2017SOT 1839 2038 2139 2238 2239 2439 2538 2539 2638 2336 WuXi 1837 1934 2037 2437 2536 2637 POSTER BOARDS 1849 AISLE 1900 AISLE 2000 2134AISLE 2100 2135 2234AISLE 2200 2235 AISLE 2300 AISLE 2400 AISLE 2500 2535 2634 AISLE 2600 Mobile Charging Station Poster Retrieval Table AppTec 1835 1935 2035 2435 2534 2635 P401–P456 | ORANGE 2032 2332 1833 1932 1933 2033 2132 2233 2433 2532 2633 1728 2228 2229 2528 2529 2628 1627 1727 1826 Charles River 2027 2126 2127 2427 327 426 427 526 527 626 827 926 1726 1825 2226
Load more

Recommended publications
  • CONTRACT RESEARCH ORGANIZATIONS (Cros) in ASIA 2014
    CONTRACT RESEARCH ORGANIZATIONS (CROs) in ASIA 2014 Pacific Bridge Medical 7315 Wisconsin Avenue, Suite 609E Bethesda, MD 20814 (301) 469-3400 (301) 469-3409 Email: [email protected] Copyright © 2014 Pacific Bridge Medical. All rights reserved. This content is protected by US and International copyright laws and may not be copied, reprinted, published, translated, resold, hosted, or otherwise distributed by any means without explicit permission. Disclaimer: the information contained in this report is the opinion of Pacific Bridge Medical, a subsidiary of Pacific Bridge, Inc. It is provided for general information purposes only, and does not constitute professional advice. We believe the contents to be true and accurate at the date of writing but can give no assurances or warranties regarding the accuracy, currency, or applicability of any of the contents in relation to specific situations and particular circumstances. TABLE OF CONTENTS CONDUCTING CLINICAL TRIALS IN ASIA ................................................................................ 1 WHY GO TO ASIAN CROS? ..................................................................................................... 1 WHAT TO WATCH OUT FOR .................................................................................................... 2 HOW TO CHOOSE A CRO ......................................................................................................... 3 WHICH COUNTRIES? ...............................................................................................................
    [Show full text]
  • Introduction to Safety Pharmacology
    What is Safety Pharmacology? 2 What is Safety Pharmacology? Safety pharmacology is a branch of pharmacology specializing in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above. Safety pharmacology studies are required to be completed prior to human exposure (i.e., Phase I clinical trials), and regulatory guidance is provided in ICH S7A and other documents. Key Concepts of Safety Pharmacology 4 Systems Primary organ systems (so-called core battery systems) are: • Central Nervous System • Cardiovascular System • Respiratory System Secondary organ systems of interest are: • Gastrointestinal System • Renal System Key aims of safety pharmacology The aims of nonclinical safety pharmacology evaluations are: • To protect Phase I clinical trial volunteers from acute adverse effects of drugs • To protect patients (including patients participating in Phase II and III clinical trials) • To minimize risks of failure during drug development and post-marketing phases due to undesirable pharmacodynamic effects The following key issues have to be considered within safety pharmacology: • The detection of adverse effects liability (hazard identification) • Investigation of the mechanism of effect (risk assessment) • Mitigation strategies (risk management) • Calculating a projected safety margin • Implications for clinical safety monitoring 7 Pharmacology vs. Toxicology? Pharmacology - the study of the action of xenobiotics,
    [Show full text]
  • Baldrick-Biosimilar-2017.Pdf
    Regulatory Toxicology and Pharmacology 86 (2017) 386e391 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Pharmacokinetic and toxicology comparator testing of biosimilar drugs e Assessing need * Paul Baldrick, PhD Professor, Executive Director, Regulatory Strategy Covance Laboratories Ltd., Otley Road, Harrogate, HG3 1PY, North Yorkshire, United Kingdom article info abstract Article history: A key element in the development of a biosimilar molecule is the comparability of the biological activity/ Received 24 January 2017 nonclinical similarity to the innovator drug. Although some regulatory guidelines are encouraging little Received in revised form or no in vivo testing, currently a common practice is to perform at least one toxicology and/or one 15 April 2017 pharmacokinetic (PK) study to assess if any different findings occur for in-life, clinical pathology and Accepted 18 April 2017 histopathological parameters or in exposure. An exercise was performed in which the results of such Available online 20 April 2017 testing were evaluated. It was found that 10 PK comparison studies in the cynomolgus monkey across 4 monoclonal (Mab) classes showed similar exposure in all cases. In 17 toxicology comparison studies with Keywords: Biosimilar 5 Mab classes performed in the same species and in 7 toxicology comparison studies with non-Mab fi Innovator biosimilars in the rat, no new/unexpected ndings were seen and drug exposure measurement gave Pharmacokinetic testing comparable values in all cases. Overall, although this work does not rule out possible utility of some Toxicology testing in vivo testing (notably in the form of stand-alone PK testing) to confirm similar exposure between the 2 Comparability exercise molecules tested, it is unclear what benefit can be gained from toxicology testing, especially if compa- Regulatory guidance rability has been demonstrated from physiochemical and in vitro characterisation.
    [Show full text]
  • Guidance for Industry, Investigators, and Reviewers: Exploratory IND
    Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology G:\7086fnl.doc 12/29/05 Contains Nonbinding Recommendations Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 A. Traditional Phase 1 Approach......................................................................................................2 B. Exploratory IND Approach ..........................................................................................................3 III. CONTENT OF IND SUBMISSIONS ............................................................................. 5 A. Clinical Information ......................................................................................................................5
    [Show full text]
  • Handbook Non-Clinical Safety Testing
    UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) HANDBOOK NON-CLINICAL SAFETY TESTING This Handbook on Non-clinical Safety Testing is designed to serve as an aid for scientists who wish to undertake non-clinical safety testing for regulatory purposes during product development. It has been developed as part of a significant and wide- ranging technology transfer and capacity building programme in the area of pre-clin- ical product development for disease endemic countries. The Non-clinical Safety Testing Handbook was produced by a Scientific Working Group (SWG) on pre-clinical issues, convened by the UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) and consisting of independent scientific specialists from around the world. The Handbook is broadly based on current safety testing guidelines including those of the Organisation for Eco- nomic Cooperation and Development (OECD) and the International Conference on Harmonisation (ICH). The Handbook will provide scientists and laboratories in disease endemic countries with the necessary technical aid for planning and implementing non-clinical safety testing programmes. The Handbook attempts to highlight the differences between syn- thetic chemical drug, vaccine and traditional herbal (botanical) medicine development programmes. TDR gratefully acknowledges the participation and support of all those involved in the production of this Handbook. For all correspondence: Dr Deborah Kioy Pre-clinical Coordinator Product Research and Development TDR/WHO Avenue Appia 20 1211 Geneva 27 – Switzerland Tel: +41 22 791 3524 Fax: +41 22 791 4854 E-mail: [email protected] TABLE OF CONTENTS FOREWORD .
    [Show full text]
  • Regulatory Toxicology
    Regulatory Toxicology Regulatory (Pharmaceutical) Toxicology Ruth Roberts Director, ApconiX Ltd Chair of Drug Discovery, University of Birmingham, UK Conflict of Interest Declaration Ruth Roberts is co-founder and co-director of Apconix, an integrated toxicology and ion channel research company that provides expert advice on nonclinical aspects of drug discovery and drug development to academia, industry, government and not-for-profit organisations. Overview/Objectives • Outline and purpose of regulatory • Outline of general toxicology testing toxicology testing for pharmaceuticals for agrochemicals and general • Overall design of the package from first time chemicals in humans (FTIH) through to marketing authorisation • Challenges and opportunities • Translation • Purpose: ensuring volunteer and patient safety in clinical trials • Attrition • Assumptions to challenge • Decision making • In vitro replacements • General Toxicology • Future Perspectives • Maximum tolerated dose (MTD)/Dose Range Finding (DRFs), “pivotal” and chronic toxicology studies • Design (doses, species, duration) and outcome • Regulatory documentation Regulatory Toxicology: Learning Objectives • Understand the purpose of pharmaceutical toxicology • Understand the pivotal role played by general toxicology studies in protecting volunteer and patient safety • Understand common principles with other sectors (agrochemicals, general chemicals) • Understand outcome of general toxicology studies and the principles and caveats of their designs • Understand the global framework
    [Show full text]
  • Drug Developement
    DRUG DEVELOPEMENT 2 Summary Acronyms used in preclinical development Life cycle of medicine Clinical trials for Beginners The Funnel Road map Example of drug development: Chemical level Pharmaceutical level Preclinical pharmacology Preclinical Toxicology Preclinical ADME 3 Preclinical development acronyms (1) ADME Absorption, distribution, metabolism, and excretion API Active pharmaceutical ingredient: any component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease. CFR Code of Federal Regulations CGMP, GMP (Current) good manufacturing practice CMC Chemistry manufacturing and controls CoA Certificate of analysis CRO Contract research organization CTM Clinical trial material Cmax Maximum plasma concentration 4 Preclinical development acronyms (2) DP Drug product: finished dosage form (for example, tablet, capsule, solution) that contains an active drug ingredient, generally in association with inactive ingredients DS Drug substance: any substance that is represented for use in a drug and that, when used in manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished drug form FDA US Food and Drug Administration FIH First in human FRS Foreign related substances GLP Good laboratory practice HPLC High performance liquid chromatography ICH International Conference on Harmonization IND Investigational New Drug application MTD Maximum tolerated dose NCE New chemical entity 5 Preclinical development acronyms (3) NDA New drug
    [Show full text]
  • Bioanalytical Systems, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) _ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2020. OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 BIOANALYTICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) INDIANA 35-1345024 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2701 KENT AVENUE WEST LAFAYETTE, INDIANA 47906 (Address of principal executive offices) (Zip code) (765) 463-4527 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of exchange on which registered Common Shares BASi NASDAQ Capital Market Securities registered pursuant to section 12(g) of the Act: None Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. YES NO _ Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES NO _ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Recent Efforts to Elucidate the Scientific Validity of Animal-Based
    Bailey and Balls BMC Medical Ethics (2019) 20:16 https://doi.org/10.1186/s12910-019-0352-3 DEBATE Open Access Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations Jarrod Bailey1* and Michael Balls2 Abstract Background: Even after several decades of human drug development, there remains an absence of published, substantial, comprehensive data to validate the use of animals in preclinical drug testing, and to point to their predictive nature with regard to human safety/toxicity and efficacy. Two recent papers, authored by pharmaceutical industry scientists, added to the few substantive publications that exist. In this brief article, we discuss both these papers, as well as our own series of three papers on the subject, and also various views and criticisms of lobby groups that advocate the animal testing of new drugs. Main text: We argue that there still remains no published evidence to support the current regulatory paradigm of animal testing in supporting safe entry to clinical trials. In fact, the data in these recent studies, as well as in our own studies, support the contention that tests on rodents, dogs and monkeys provide next to no evidential weight to the probability of there being a lack of human toxicity, when there is no apparent toxicity in the animals. Conclusion: Based on these data, and in particular on this finding, it must be concluded that animal drug tests are therefore not fit for their stated purpose. At the very least, it is now incumbent on—and we very much encourage—the pharmaceutical industry and its regulators to commission, conduct and/or facilitate further independent studies involving the use of substantial proprietary data.
    [Show full text]
  • In Silico and in Vitro Testing Resources Alcyomics, Ltd., Offers In
    In Silico and In Vitro Testing Resources Alcyomics, Ltd., offers in vitro human-based pre-clinical drug safety testing. It manufactures SkimuneTM (human skin explants for safety and efficacy testing) and offers immunogenicity services, efficacy testing of immunomodulators, hypersensitivity testing, potency assessment, cellular and cytokine assays and safety assessment services. AllCells, LLC, offers more than 150 primary cell types and related RNA and cDNA from normal and disease-state tissues.Cell types include stem cells (progenitor, CD34+, etc.), hematopoietic, human hematologic disease, endothelial, dendritic, HUVEC cells and many others. It also offers services such as drug discovery, device validation, flow cytometry and cell sorting, tissue culture protein analysis and genotyping as well as stem cell and immune assays. Alternative Toxicity Services offers high-content screening for evidence-based acute general toxicity and neurotoxicity. APSciences, Inc., offers Integrated Discrete Multiple Organ Co-culture (IdMOC) technology, which is an in vitro model consisting of multiple, inner wells within a larger interconnecting chamber. It is based on the concept that the multiple organs in a human (or other animal) are physically separated but interconnected by the systemic circulation (i.e., blood). IdMOC can be used to evaluate drug toxicity, drug metabolism and drug distribution as well as anti-cancer drugs for cytotoxicity, efficacy and mechanism of action. Asterand, PLC, provides high quality, well characterised human tissue through its worldwide network of 75 active collaborative donor institutions and human tissue-based research solutions to drug discovery scientists. It also provides a collaborative scientific approach to deliver human tissue-based data ontarget and biomarker validationas well ascompound potency, effect and safety.
    [Show full text]
  • Toxexpo Directory
    ToxExpoTM Directory 54th Annual Meeting & ToxExpoTM March 22–26, 2015 San Diego Convention Center San Diego, California TRANSLATING DISCOVERIES Reaching the clinic can be a daunting task. Let the experts at Charles River be your guide, every step of the way. Our expansive safety assessment portfolio is supported by advanced imaging and biomarker services that provide a deep scientific understanding of your compound and produce the high quality data you need to optimize your drug development program. Visit us at booth 1326 to learn more. every step of the way. www.criver.com/SOT2015 ToxExpo Directory Table of Contents ToxExpo Exhibit Hall Hours Supporters .......................................................................... 2 Monday, March 23 9:00 AM–4:30 PM Exhibit Hall Map ...............................................................4 2015 Exhibitors ..................................................................6 Tuesday, March 24 8:30 AM–4:30 PM General Information ....................................................... 10 Wednesday, March 25 8:30 AM–4:30 PM Exhibitor-Hosted Sessions ...........................................14 Exhibitor Descriptions ..................................................22 Exhibitor Product/Service Category Listing ....... 136 Follow us on Twitter at @ToxExpo and @SOToxicology Recording, Photography, and Cell Phone Policy SOT Badge Policy—altering of SOT badges in any way is strictly prohibited. All attendees must be officially registered • Photographing exhibit booths is prohibited. for the
    [Show full text]
  • Pharmacology, Toxicology & Pharmaceutical Science
    PHARMACOLOGY, TOXICOLOGY & PHARMACEUTICAL SCIENCE 2017 CATALOG 1 Elsevier Science and Technology Books deliver targeted content that enables the understanding and application of research. Year after year readers use our books to drive advancements in their fields. Tools and content on ScienceDirect offer: • Full-text version online or • Portable content available on download and print with no computers, tablets and smartphones digital rights management to give users information in the restrictions (DRM) format that best suits their needs • Multi-user/concurrent • Integrated book and journal access at any time from any content for easier access to related location to expand the reach materials of the content to your patrons • Free MARC records to drive discoverability and usage Our foundational content—including Reference Modules, unique resources that are trustworthy, current, discoverable, and hosted on ScienceDirect—complements original research in journal articles. Our Legacy Collection on ScienceDirect, in 20 subject areas, ensures that valuable historical content is discoverable and searchable, saving time and resources. Table of Contents Stay Connected Biomedical Science & Medicine.........................................2 Stay connected with Life Sciences........................................................................6 Elsevier on Facebook, Twitter, YouTube and Serials.................................................................................58 LinkedIn. These sites are full of news, resources, Titles Index.........................................................................67
    [Show full text]